QMSMEDIQMS Medical Allied Services Limited
Healthcare · Medical Instruments & Supplies · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
QMS Medical Allied Services Limited distributes medical and healthcare devices in India. The company also manufactures and sells glucometers, pulse oximeters, IR thermometers, BP monitors, anatomy sets, neurology kits, orthopedic aids, and weighing scales, etc.; and operates QMSMEDS, an e-commerce platform that sells healthcare devices of various brands. In addition, the company provides diagnostic and patient management services, including ambulatory blood pressure tracking, continuous blood glucose and blood pressure/glucose monitoring, tonometry, and HbA1C services. Further, it offers Educamedics, which provides customized scientific content in the form of conferences, online courses, webinars, recorded lectures, and others. Additionally, the company offers chemical and chemical products, pharmaceuticals, and medicinal chemical and botanical products. QMS Medical Allied Services Limited was founded in 1994 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on QMSMEDI — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why buy
- • Revenue growth: 22.3% YoY
- • Profit growth: 25.0% YoY
- • Debt/Equity: 0.65
- • RSI: 66
- • Price vs EMA21: above
- • Price vs SMA50: above
Bull case
- • Revenue growth: 22.3% YoY
- • Profit growth: 25.0% YoY
- • Debt/Equity: 0.65
- • RSI: 66
Bear case
- • ROE: 9.7%
- • Dividend yield: 0.32%
- • MACD: bearish
- • Volume: 0.9x 20-day average
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • ROE: 9.7%
- • Dividend yield: 0.32%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹7.14). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.